JAK/STAT pathway inhibitor has been used in clinic trial for several diseases. However, the adverse effect of systematic administration of JAK/STAT pathway inhibitors on cellular function is largely unknown. In the present study, alteration of metabolites in C57BL/6 mice serum were characterized using metabonomic analysis after WP1066 (a JAK/STAT pathway inhibitor) treatment (20 mg/kg.bw, once every 2 days for 2 weeks). 1H NMR spectroscopy was used to detect the effect of WP1066 on metabolites component, and the metabolite profile were analyzed by principle component analysis (PCA) and orthogonal partial least squares (OPLS) analysis. Results showed that the level of N-methylnicotinamide was significantly downregulated, while cis-aconitate, oxaloacetate and acetamide were significantly upregulated in mice serum in response to JAK/STAT pathway inhibition. The above metabolic changes are associated with alterations in energy metabolism, indicating that parameters associated with metabolism unbalance may be used for monitoring the efficiency and adverse effect of JAK/STAT pathway inhibitor.
ZHAO Xin
,
XIAO Xiong-jie
,
GAO Dong-li
,
ZHANG Xian-rong
. 1H NMR Study on Serum Metabonomic Alterations Induced by JAK/STAT Pathway Inhibitor in C57BL/6 Mice[J]. Chinese Journal of Magnetic Resonance, 2018
, 35(2)
: 198
-203
.
DOI: 10.11938/cjmr20182630
[1] VILLARINO A V, KANNO Y, O'SHEA J J. Mechanisms and consequences of JAK-STAT signaling in the immune system[J]. Nat Immunol, 2017, 18(4):374-384.
[2] DODINGTON D W, DESAI H R, WOO M. JAK/STAT-Emerging players in metabolism[J]. Trends Endocrinol Metab, 2018, 29(1):55-65.
[3] O'SHEA J J, PLENGE R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease[J]. Immunity, 2012, 36(4):542-550.
[4] MOH A, ZHANG W, YU S, et al. STAT3 sensitizes insulin signaling by negatively regulating glycogen synthase kinase -3 beta[J]. Diabetes, 2008, 57(5):1227-1235.
[5] CORBIT K C, CAMPOREZ J P, TRAN J L, et al. Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance[J]. JCI Insight, 2017, 2(3):e91001.
[6] CERNKOVICH E R, DENG J, BOND M C, et al. Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity[J]. Endocrinology, 2008, 149(4):1581-1590.
[7] KALENECKER D, MUELLER K M, BENEDIKT P, et al. Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice[J]. Diabetologia, 2017, 60(2):296-305.
[8] LEE E B, FLEISCHMANN R, HALL S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis[J]. N Engl J Med, 2014, 370(25):2377-2386.
[9] WINTHROP K. The emerging safety profile of JAK inhibitors in rheumatic disease[J]. Nat Rev Rheumatol, 2017, 13(5):320.
[10] NICHOLSON J K, WILSON I D. Opinion:understanding ‘global’ systems biology:metabonomics and the continuum of metabolism[J]. Nat Rev Drug Discov, 2003, 2(8):668-676.
[11] REAGAN-SHAW S, NIHAL M, AHMAD N. Dose translation from anima to human studies revisited[J]. FASEB J, 2008, 22(3):659-661.
[12] KONG L Y, ABOU-GHAZAL M K, WEI J, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells[J]. Clin Cancer Res, 2008, 14(18):5759-5768.
[13] CRAIG A, CLOARCO O, HOLMES E, et al. Scaling and normalization effects in NMR spectroscopic metabonomic data sets[J]. Anal Ch em, 2006, 78(7):2262-267.
[14] GOVINDARAJU V, YOUNG K, MAUDSLEY A A. Proton NMR chemical shifts and coupling constants for brain metabolites[J]. NMR Biomed, 2000, 13(3):129-153.
[15] MAGNI G, AMICI A, EMANUELLI M, et al. Enzymology of NAD+ homeostasis in man[J]. Cell Mol Life Sci, 2004, 61(1):19-34.
[16] PRZYGODZKI T, KAZMIERCZAK P, SIKORA J, et al. 1-methylnicotinamide effects on the selected markers of endothelial function, inflammation and haemostasis in diabetic rats[J]. Eur J Pharmacol, 2010, 640(1-3):157-162.
[17] MATEUSZUK L, JASZTAL A, MASLAK E, et al. Anti-atherosclerotic effects of 1-methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient mice:a comparison with nicotinic acid[J]. J Pharmacol Exp Ther, 2016, 356(2):514-524.
[18] STRÖM K, MORALES-ALAMO D, OTTOSSON F, et al. N1-methylnicotinamide is a signalling molecule produced in skeletal muscle coordinating energy metabolism[J]. Sci Rep, 2018, 8(1):3016.
[19] VAN DER BLIEK A M, SEDENSKY M M, MORGAN P G. Cell Biology of the Mitochondrion[J]. Genetics, 2017, 207(3):843-871.
[20] DELAVAL E, PERICHON M, FRIGUET B. Age-related impairment of mitochondrial matrix aconitase and ATP-stimulated protease in rat liver and heart[J]. Eur J Biochem, 2004, 271(22):4559-4564.
